Aiming at PD-L1 expressed in tumor cell surface and PD-1 targets expressed in T cells of immune system, Innovent Biologics, Inc. has launched bis-specific combined drug, made solid fundamental research in terms of its pharmacokinetics and metabolomics, and is currently carrying out clinical trials (104). This evidence concerns the gene CD274 and neoplasm.